SkinBioTherapeutics (GB:SBTX) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
SkinBioTherapeutics plc has achieved remarkable growth through strategic acquisitions and expanding its product lineup, resulting in a projected turnover of £6.3 million for FY25. The company has successfully extended its Croda partnership and launched new products in Europe, bolstering its presence in the skin health market. With these developments, SkinBioTherapeutics anticipates becoming cash flow positive by FY25, minimizing the need for further fundraising.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.
